// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Effect of Ofatumumab on Lymphocytes and Neutrophils in Patients with Relapsing Multiple Sclerosis over 4 Years

Amit Bar-Or - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Teriflunomide

Development and Interrelation of Spatiotemporal Patterns of Brain Atrophy and Lesions in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Giordano Gentile - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon beta-1a

Development and Interrelation of Whole-Brain Atrophy and Lesion Volume in Patients with a First Clinical Demyelinating Event in the REFLEX/ION Study

Rozemarijn Mattiesing - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Interferon beta-1a

Pregnancy Outcomes in Ofatumumab-Treated Patients with Multiple Sclerosis

Kerstin Hellwig - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Congenital anomalies

ofatumumab Intravenous

Exploratory Analysis of Serum GDF-15 Levels in Patients Receiving Subcutaneous Interferon β-1a in the REFLEX Trial

Mali Coray - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Ectodermal dysplasia-syndactyly syndrome

Interferon

Post-Approval Safety of Subcutaneous Interferon β-1a in the Treatment of Multiple Sclerosis, with Particular Reference to Respiratory Viral Infections

Mark S Freedman - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Multiple Sclerosis

Interferon

Fetal Exposure with Ponesimod Treatment across Clinical Development Studies

Mauricio Rosas-Ballina - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ponesimod

Ponesimod in Relapsing Forms of Multiple Sclerosis - Long-Term Pooled Safety Results from the Clinical Development Program

Mauricio Rosas-Ballina - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ponesimod

Inverse Relationship between Plasma Neurofilament Light Chain Concentration and Symbol Digit Modalities Test Scores in the Sunbeam Trial of Ozanimod in RMS

Sarah Harris - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Ozanimod

A Post Hoc Analysis of Immunoglobulin Levels in Patients with Relapsing Multiple Sclerosis Treated with Ozanimod in Phase 3 Trials

Sarah Harris - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Interferon

A Systematic Literature Review of Immunoglobulin Levels Among B-Cell–Depleting Therapies and Risk of Infections in Relapsing Multiple Sclerosis

Shiv Saidha - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Ocrelizumab

A 20-Year Review of Race and Ethnicity in Multiple Sclerosis Rehabilitation Trials: Work in Progress

Afolasade Fakolade - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Treatment of Acute Optic Neuritis and MS Relapses: A Survey of Clinician Attitudes, Perspectives, and Clinical Reasoning

Emily M Schorr - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Methylprednisolone

Long-Term Efficacy for Patients Receiving Cladribine Tablets (3.5 mg/kg Over 2 years) in Clarity/Clarity Extension: A Post Hoc Analysis of Classic-MS

Gavin Giovannoni - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Ectodermal dysplasia-syndactyly syndrome

Cladribine

Patient-Reported Outcomes from NOVA: A Randomized Controlled Study of the Efficacy of Natalizumab 6-Week Dosing Vs Continued 4-Week Dosing for MS

Lana Zhovtis Ryerson - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

Natalizumab

MRI Use in MS Clinical Practice: Results of the 2022 CMSC Survey

Anthony Traboulsee - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Physicians and Patients Have Different Perspectives on Burden of Hidden Symptoms of Multiple Sclerosis to Patients

Hoa H. Le - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Fatigue in Active and Nonactive Primary and Secondary Progressive Multiple Sclerosis Patients in the United States

Crystal Watson - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Multiple Sclerosis

N/A

Post Hoc Analysis of Nabiximols Efficacy By Concomitant Medication Use in 2 Enriched Placebo-Controlled Randomized Clinical Trials (RCTs)

Faria Amjad - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Tetrahydrocannabinol

A New Mechanism-Driven Framework to Define Progression in MS – a Proposal from the International Advisory Committee on Clinical Trials in MS

Jennifer Graves - Annual Meeting of Consortium of Multiple Sclerosis Centers (CMSC) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved